Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-response Study of Dryvax in Previously Vaccinated Adults
NCT00050505Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Oct 2002
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dryvax in smallpox (3 cohorts), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Proportion of vaccinees demonstrating a 'take' and Safety data regarding the three doses of vaccine. Started Oct 2002; status: completed.
02
Drugs
dryvax
03
Conditions
smallpox
Beyond the preview
Go deeper on NCT00050505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00050505.